Skip to main content
. 2016 Dec 27;18(1):44. doi: 10.3390/ijms18010044

Figure 5.

Figure 5

Schematic model depicting the mechanisms of action underlying obatoclax-induced antiproliferation. Obatoclax targets cyclin D1 for proteasome-mediated degradation to downregulate cyclin D1, leading to delayed G1-phase cell cycle progression, and the consequent inhibition of cell proliferation in a panel of human colorectal cancer cell lines.